Table 3.
Univariate analysis of clinical factors affecting progression-free survival and overall survival (n=171)
| Variable | Progression-free survival |
Overall survival |
||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age, ≥ 65 yr | 1.08 (0.73-1.58) | 0.710 | 1.61 (0.98-2.63) | 0.059 |
| Male sex | 0.61 (0.39-0.96) | 0.031 | 1.49 (0.76-2.92) | 0.246 |
| ECOG PS, 2-3 | 1.02 (0.53-1.96) | 0.950 | 1.64 (0.81-3.32) | 0.166 |
| Underlying lung disease | 1.17 (0.70-1.94) | 0.552 | 1.30 (0.69-2.43) | 0.412 |
| (Ex-)Smoker | 0.80 (0.52-1.21) | 0.283 | 1.73 (0.93-3.23) | 0.086 |
| FVC (%) | 1.01 (1.00-1.03) | 0.181 | 1.00 (0.98-1.02) | 0.772 |
| FEV1 (L) | 0.99 (0.71-1.37) | 0.931 | 0.86 (0.57-1.31) | 0.487 |
| DLCO (%) | 1.00 (0.99-1.01) | 0.477 | 0.99 (0.97-1.00) | 0.083 |
| Clinical stage, III | 1.50 (1.17-1.93) | 0.002 | 1.56 (1.13-2.15) | 0.006 |
| Pathology, SqCC | 1.28 (0.92-1.76) | 0.141 | 0.86 (0.55-1.33) | 0.487 |
| EGFR, mutation | 1.30 (0.74-2.28) | 0.362 | 0.48 (0.18-1.26) | 0.137 |
| PD-L1 positive (> 1%) | 0.76 (0.48-1.20) | 0.242 | 0.71 (0.39-1.28) | 0.259 |
| Total RT dose, ≥ 66 Gy | 0.90 (0.61-1.31) | 0.582 | 1.04 (0.65-1.69) | 0.860 |
| Chemotherapy, TP | 0.68 (0.45-1.03) | 0.070 | 0.57 (0.35-0.95) | 0.032 |
| Use of durvalumab | 0.68 (0.47-1.00) | 0.050 | 0.53 (0.32-0.87) | 0.011 |
| Interval between CCRT and durvalumab, ≤ 42 daysa) | 0.62 (0.29-1.30) | 0.203 | 0.62 (0.23-1.71) | 0.359 |
CI, confidence interval; DLCO, diffusing capacity of the lung for CO; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; HR, hazard ratio; PD-L1, programmed cell death ligand 1; RT, radiotherapy; SqCC, squamous cell carcinoma; TP, paclitaxel/cisplatin.
a)
Only 89 patients who received durvalumab after concurrent chemoradiotherapy were included.